NeuroPace, Inc. (NASDAQ:NPCE) Shares Bought by Barclays PLC

Barclays PLC increased its stake in NeuroPace, Inc. (NASDAQ:NPCE) by 346.0% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 20,633 shares of the company’s stock after acquiring an additional 16,007 shares during the period. Barclays PLC owned approximately 0.07% of NeuroPace worth $144,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in NPCE. Rhumbline Advisers purchased a new position in shares of NeuroPace in the 2nd quarter valued at $111,000. Financial Advocates Investment Management boosted its position in shares of NeuroPace by 20.0% in the third quarter. Financial Advocates Investment Management now owns 18,000 shares of the company’s stock worth $125,000 after buying an additional 3,000 shares during the period. XTX Topco Ltd grew its stake in shares of NeuroPace by 56.1% in the second quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock valued at $182,000 after buying an additional 8,643 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of NeuroPace during the 2nd quarter valued at about $257,000. Finally, Acadian Asset Management LLC lifted its position in NeuroPace by 46.0% during the 2nd quarter. Acadian Asset Management LLC now owns 68,918 shares of the company’s stock worth $520,000 after acquiring an additional 21,703 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

Insider Buying and Selling

In other news, major shareholder Ltd. Kck sold 6,900 shares of the company’s stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $6.57, for a total transaction of $45,333.00. Following the completion of the sale, the insider now directly owns 5,510,957 shares of the company’s stock, valued at $36,206,987.49. This represents a 0.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold a total of 246,239 shares of company stock valued at $1,363,038 over the last three months. Company insiders own 22.20% of the company’s stock.

NeuroPace Stock Performance

NPCE stock opened at $12.42 on Wednesday. The stock’s fifty day moving average is $10.03 and its two-hundred day moving average is $8.13. The stock has a market capitalization of $370.71 million, a price-to-earnings ratio of -12.42 and a beta of 2.02. The company has a debt-to-equity ratio of 6.03, a quick ratio of 4.77 and a current ratio of 5.59. NeuroPace, Inc. has a 1 year low of $5.45 and a 1 year high of $18.15.

NeuroPace (NASDAQ:NPCE) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.07. The business had revenue of $21.06 million for the quarter, compared to analyst estimates of $19.33 million. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. During the same quarter last year, the business earned ($0.28) earnings per share. On average, research analysts predict that NeuroPace, Inc. will post -1 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. JPMorgan Chase & Co. upped their price target on shares of NeuroPace from $9.00 to $14.00 and gave the company an “overweight” rating in a report on Tuesday, December 17th. Wells Fargo & Company lowered their price target on NeuroPace from $15.00 to $13.00 and set an “overweight” rating for the company in a report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, NeuroPace has an average rating of “Moderate Buy” and an average price target of $15.00.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.